1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502–1517.
2.
Marrodan M, Alessandro L, Farez MF, et al. The role of infections in multiple sclerosis. Mult Scler 2016; 25: 891–901.
3.
Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006; 67: 652–659.
4.
Loebermann M, Winkelmann A, Hartung HP, et al. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2012; 8: 143–151.
5.
Reyes S, Ramsay M, Ladhani S, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol 2020; 20: 435–445.
6.
Riva A, Barcella V, Benatti SV, et al. Vaccinations in patients with multiple sclerosis: a Delphi consensus statement. Mult Scler 2021; 27(3): 347–359, doi: 10.1177/1352458520952310.
7.
Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine preventable infections and immunization in multiple sclerosis. Re-port of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2019; 93(13): 584–594.
8.
Programy Lekowe Ministerstwa Zdrowia: Choroby nieonkologiczne. Ministerstwo Zdrowia – Portal Gov.pl [cited 12.11.2022]. Available from URL: www.gov.pl (in Polish).
9.
National multiple sclerosis society (nmss) [cited 28.03.2019]. Available from URL: /www.nationalmssociety.org/living-well-with-ms/diet-exercise-healthy-behaviors/vaccinations.
10.
Williamson EM, Chahin S, Berger J. Vaccines in multiple sclerosis. Current Neurol Neuroscience Rep 2016; 16: 36.
11.
Pellegrino P, Carnovale C, Perrone V, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine 2014; 32: 4730–4735.
12.
Michiels B, Govaerts F, Remmen R, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011; 29(49): 9159–9170.
13.
Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology 2020; 95: e1999–e2008, doi: 10.1212/WNL.0000000000010380.
14.
Filippi M, Capra R, Centonze D, et al. Therapeutic recommendations and seasonal infuenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. J Neurol 2021; 268: 1540–1543.
15.
Moiola L, Riva A, Nicoletti F, et al. Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. Curr Neuropharmacol 2021; doi: 10.2174/1570159x20666211217160451.
16.
Mormile R. Hepatitis B, Virus (HBV) infection and multiple sclerosis: one more reason to undergo vaccination? Immunol Lett 2015; 165: 60–61.
17.
Langer-Gould A, Gian L, Tartof S, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol 2014; 71: 1506–1513.
18.
Martínez-Sernández V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis b vaccination: a critical systematic review of scientific production. J Neurol 2013; 260: 1951–1959.
19.
Confavreux C, Suissa S, Saddier P, et al. Vaccines in multiple sclerosis study group: vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 344: 319–326.
20.
Keyser J, de. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 1998; 26: 319.
21.
Hernan M, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006; 67: 212–215.
22.
Kaufman M, Pardo G, Rossman H, et al. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 2014; 341: 22–27.
23.
McCarthy CL, Tuohy O, Compston DA, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013; 81: 872–876.
24.
Boulton C, Meiser K, David OJ, et al. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. Int J Clin Pharmacol 2012; 52: 1879–1890.
25.
Scheller N, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nerv-ous system. JAMA 2015; 313: 54–61.
26.
Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014; 13: 736–741.
27.
Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197–1206.
28.
Ristori G, Romano S, Cannoni S, et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 2014; 82: 41–48.
29.
Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neurophysiol Neurosci 2015; 2: e70.
30.
Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011; 68: 1267–1271.
31.
National Multiple Sclerosis Society (nmss). Vaccinations. [cited 5.01.2022]. Available from URL: nationalmssociety.org.
32.
Nojszewska M, Kalinowska A, Adamczyk-Sowa M. et al. Stanowisko dot. szczepień przeciwko SARS-CoV-2 dostępnymi w Polsce szczepionkami u pacjentów z SM [cited 5.01.2022]. Available from URL: ptneuro.pl (in Polish).
33.
Nojszewska M, Kalinowska A, Adamczyk-Sowa M, et al. Stanowisko dotyczące 3. dawki szczepionki mRNA przeciwko SARS-CoV-2 u pacjentów z SM [cited 5.01.2022]. Available from URL: https://ptneuro.pl/aktualnosc/stanowisko-dotyczace-3-dawki-szczepionki-mrna-przeciwko-sars-cov-2-u-pacjentow-z-sm (in Polish).
34.
Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Committee on Infectious Diseases. Pediatrics 2009; 123: 1412–1420.
35.
Podsumowanie – Szczepionka przeciw ospie wietrznej [cited 5.01.2022]. Available from URL: https://szczepienia.pzh.gov.pl/szczepionki/ospa-wietrzna (in Polish).
